HOMA-IR and TyG Index: Track Insulin Resistance Early

What HOMA-IR and the TyG Index Actually Measure

Insulin resistance describes a state in which the body's cells respond less efficiently to insulin, so the pancreas compensates by producing more of it to keep blood sugar controlled. For a while, that compensation works, and fasting glucose can look normal even as fasting insulin climbs. Direct measurement of insulin sensitivity, through a procedure called the euglycemic clamp, is accurate but impractical for routine use. HOMA-IR and the TyG index exist as accessible surrogate markers that estimate the same thing from ordinary blood tests.

HOMA-IR stands for Homeostatic Model Assessment of Insulin Resistance. It combines [fasting insulin](/biomarkers/fasting-insulin) and [fasting glucose](/biomarkers/fasting-glucose) into a single index. Because it includes fasting insulin, HOMA-IR captures the compensatory rise in insulin directly, which is part of why it can flag a change early.

The TyG index takes a different route. Instead of insulin, it uses [fasting triglycerides](/biomarkers/triglycerides) alongside fasting glucose. Triglycerides tend to rise as insulin resistance develops, so the combination of glucose and triglycerides serves as a proxy. The practical advantage is that many people already have both values from a standard fasting lipid panel and a basic metabolic panel, so the TyG index often requires no additional test at all. Both markers are estimates, not direct measurements, and both are meant to be read as trends rather than one-off verdicts.

How to Calculate HOMA-IR and TyG, and Why the Ranges Vary

Both markers use published, widely cited formulas. The TyG index formula, as reported in the endocrinology literature, is the natural log of fasting triglycerides multiplied by fasting glucose, divided by two. HOMA-IR is commonly calculated from fasting insulin and fasting glucose. The table below summarizes the inputs, the standard formulas, and the tests each one draws from.

|---|---|---|---|

A few practical notes make these numbers trustworthy over time. First, both formulas assume a genuine fasting state, typically 8 to 12 hours, because non-fasting glucose, insulin, and triglycerides will distort the result. Second, unit consistency matters. The formulas above use conventional US units (mg/dL for glucose and triglycerides, uU/mL for insulin), and if your lab reports in different units you need to convert before calculating. Third, the value of either marker comes from repeating it under the same conditions. A HOMA-IR or TyG index calculated from a random afternoon draw after lunch is not comparable to one from a proper morning fast, and comparing the two would be misleading.

Once you have a number, it is tempting to want a single cutoff that separates insulin sensitive from insulin resistant, and the literature does discuss thresholds. In practice, published reference ranges for both HOMA-IR and the TyG index vary meaningfully across populations, ethnicities, laboratories, and the specific insulin assay used, which is one reason there is no single universally agreed diagnostic cutoff. Reviews in the endocrinology literature discuss both markers in the context of metabolic syndrome and cardiovascular risk, and note that thresholds are best interpreted against the reference range of the specific lab and population rather than a fixed number.

Because of that variability, the most defensible way to use these markers on your own is directional. A rising HOMA-IR or TyG index across repeated, comparable fasting draws is a trend worth discussing. A single value sitting near a published cutoff is not a diagnosis. Whether any specific number reflects insulin resistance, prediabetes, or normal metabolic function is a clinical determination that only your provider can make, using your full history, exam, and any confirmatory testing they judge appropriate. Treat the calculated markers as a conversation starter, not a conclusion.

MyProtocolStack does not calculate a diagnosis from these numbers. What a tracking tool does well is store your fasting inputs, keep the conditions consistent, and let you visualize the calculated trend over time so the direction of travel is obvious at a glance.

Why These Markers Move Before HbA1c

The most useful property of HOMA-IR and the TyG index is timing. HbA1c reflects roughly 90 days of average blood glucose, and glucose itself tends to stay controlled until the body's insulin compensation starts to fail. That means HbA1c can remain comfortably in range while insulin resistance is already building underneath it. HOMA-IR, because it includes fasting insulin, can register the compensatory rise in insulin before glucose or HbA1c shift. The TyG index picks up the associated triglyceride changes on a similar early timeline. Both markers often begin to rise years before HbA1c moves, which is precisely why people who track their metabolic health longitudinally value them as an early signal rather than a late one.

This does not make HbA1c redundant. HbA1c remains a core, clinically established measure, and it belongs in any serious metabolic tracking record. The point is complementary information. Watching [HbA1c](/biomarkers/hba1c), HOMA-IR, and the TyG index together gives you a fuller and earlier picture than any one of them alone, and it gives your clinician more context to work with.

The 2026 WEAR-ME Study: Wearables Plus Bloodwork

The clearest recent signal that this space is moving came in 2026. Google Research's WEAR-ME study, published in Nature (vol 652, pp 451-461, 2026), trained deep neural networks on wearable time-series data combined with routine bloodwork to predict insulin resistance, using HOMA-IR as the ground-truth reference. The headline result is that adding wearable data materially improved prediction. The model reached an AUROC of 0.88 when wearable data was included, up from 0.76 without wearables, and reported 93% sensitivity in obese or sedentary participants.

Two things are worth keeping in perspective. First, the study predicted insulin resistance against HOMA-IR as the reference standard, which reinforces how central these calculated markers have become as a benchmark. Second, this is a predictive model built on population data, not a personal diagnostic you can run at home, and its performance figures describe the model, not any individual. It is a strong indication that everyday signals, movement, heart rate patterns, and routine labs, carry real information about metabolic health. For someone tracking their own data, the practical lesson is not that a wearable replaces a blood draw, but that consistent fasting labs plus consistent lifestyle data together tell a richer story than either alone.

What to Track: Biomarkers Worth Monitoring

If you want a longitudinal metabolic record that is genuinely useful in a clinical conversation, the following markers are the ones researchers and clinicians most often discuss around insulin resistance. None of this is a recommendation to test or treat. It is a list of what is commonly tracked so you can organize your own data and review it with your provider.

Tracking these consistently, from the same fasting conditions, is what turns scattered lab results into a trend line you and your provider can actually read. If your care involves GLP-1 medications such as [semaglutide](/peptides/semaglutide) or [tirzepatide](/peptides/tirzepatide), these same metabolic markers are commonly monitored over time as well, and keeping them in one organized record makes each provider conversation easier. You can browse plain-language explanations of each test in the full [biomarker library](/biomarkers).

[Track your fasting labs and calculated metabolic markers over time with MyProtocolStack.](/auth/login?mode=signup)

How to Track Insulin Resistance Over Time

Turning these markers into something useful is mostly about consistency and patience. A single HOMA-IR or TyG index is a snapshot, and snapshots can mislead. A trend line built from comparable draws is what carries signal. The practical approach is straightforward: draw your fasting labs under the same conditions each time, calculate or record both markers, log the values with their dates, and look at the direction of travel over months rather than reacting to any one result. When you review the trend with your clinician, you are giving them cleaner information than a lone number pulled from a busy visit.

The reason a tracking tool helps here is that it removes the friction that causes people to give up. Storing your fasting inputs in one place, keeping the fasting conditions consistent, visualizing the calculated markers next to HbA1c and your lipids, and having the full history ready for a provider conversation are exactly the tasks that a structured record does better than a folder of PDFs. MyProtocolStack organizes and visualizes that data so the trend is obvious. It does not interpret it for you, and it is not a substitute for your clinician's judgment. The goal is simple: bring good, consistent data to the people qualified to interpret it.

Frequently Asked Questions

What is the TyG index and how is it calculated?

The TyG index is a calculated marker that estimates insulin resistance using two values from a standard fasting blood draw: fasting triglycerides and fasting glucose. The standard published formula is the natural log of fasting triglycerides (mg/dL) multiplied by fasting glucose (mg/dL), divided by two, written as Ln[fasting triglycerides x fasting glucose / 2]. Because both inputs come from a routine fasting lipid panel plus fasting glucose, the TyG index usually requires no special test. It is an estimate meant to be tracked as a trend, and any interpretation of your value should be confirmed with your clinician.

What is HOMA-IR and how is it calculated?

HOMA-IR, short for Homeostatic Model Assessment of Insulin Resistance, is a calculated marker derived from fasting glucose and fasting insulin. Because it includes fasting insulin, it can reflect the body's compensatory rise in insulin, which is part of why it may register a change early. Both inputs come from a standard fasting blood draw, so no special test is needed. Like the TyG index, HOMA-IR is a surrogate estimate rather than a direct measurement, and your provider is the right person to interpret what a given value means for you.

Can HOMA-IR or the TyG index diagnose insulin resistance or diabetes?

No. HOMA-IR and the TyG index are surrogate markers that estimate insulin resistance, and they are useful for tracking trends over time, but they do not diagnose insulin resistance, prediabetes, or diabetes on their own. Published reference ranges and cutoffs vary by population, ethnicity, laboratory, and insulin assay, so there is no single universal threshold. Diagnosis is a clinical determination that only your provider can make, using your full history and any confirmatory testing they judge appropriate. Use these markers as a conversation starter, not a conclusion.

Why do HOMA-IR and the TyG index rise before HbA1c?

HbA1c reflects roughly 90 days of average blood glucose, and glucose tends to stay controlled until the body's insulin compensation begins to fail, so HbA1c can look normal while insulin resistance is already building. HOMA-IR includes fasting insulin, so it can capture the compensatory rise in insulin before glucose or HbA1c shift. The TyG index picks up associated triglyceride changes on a similar early timeline. Both markers often begin to rise years before HbA1c moves, which is why people track them together as an earlier signal alongside HbA1c rather than in place of it.

What was the 2026 WEAR-ME study and what did it find?

The WEAR-ME study, from Google Research and published in Nature (vol 652, pp 451-461, 2026), trained deep neural networks on wearable time-series data combined with routine bloodwork to predict insulin resistance, using HOMA-IR as the ground-truth reference. Adding wearable data raised the model's AUROC to 0.88, up from 0.76 without wearables, and the study reported 93% sensitivity in obese or sedentary participants. It is a population-level predictive model, not a personal diagnostic, but it underscores how central HOMA-IR has become as a benchmark and how much information everyday signals plus routine labs can carry about metabolic health.

Sources

1. Nature, WEAR-ME study on predicting insulin resistance from wearables and routine blood biomarkers, vol 652, pp 451-461, 2026. https://www.nature.com/articles/s41586-026-10179-2

2. Google Research, "Insulin resistance prediction from wearables and routine blood biomarkers." https://research.google/blog/insulin-resistance-prediction-from-wearables-and-routine-blood-biomarkers/

3. National Library of Medicine, PubMed Central article on HOMA-IR and the TyG index. https://pmc.ncbi.nlm.nih.gov/articles/PMC13061641/

4. touchENDOCRINOLOGY, "HOMA-IR, TyG Index and Metabolic Syndrome." https://touchendocrinology.com/cardiovascular-risk/journal-articles/homa-ir-tyg-index-and-metabolic-syndrome/

*MyProtocolStack is a tracking and education tool, not medical advice, diagnosis, or treatment, and you should always consult a qualified healthcare professional before making any changes to your health protocol.*